Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Inclusion Criteria:

- Histologically confirmed diagnosis of multiple myeloma.

- Received prior autologous stem cell transplantation as first line therapy for multiple
myeloma with subsequent disease relapse/progression.

- Refractory to or intolerant of lenalidomide maintenance following first autologous
stem cell transplantation. Refractory is defined as disease relapse/progression on
therapy or within 60 days of completing therapy. Intolerance is defined as the
inability to administer ≥ 10 mg per day due to toxicity.

- All US study participants must be registered into the mandatory POMALYST REMS® program
and be willing and able to comply with the requirements of the POMALYST REMS® program.
For Canadian sites, patients will followed according to the Pomalidomide pregnancy
prevention program

- Females of reproductive potential within the US must agree to adhere to the scheduled
pregnancy testing as required in the POMALYST REMS® program. For Canadian sites,
patients will followed according to the Pomalidomide pregnancy prevention program

- Candidate for second autologous stem cell transplantation per local institution's
guidelines with at least 2x106/kg CD34+ autologous stem cells available for
transplantation.

- At least 18 and no more than 75 years of age at enrollment.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Normal bone marrow and organ function as defined as ALL of the following:

- Absolute neutrophil count ≥ 1000/mm^3

- Platelets ≥ 75,000/mm^3 (transfusions not permitted within 7 days of screening)

- Total bilirubin ≤ 2.0 x institutional upper limit of normal (IULN)

- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN

- Creatinine clearance ≥ 15 mL/min

- Females of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control, abstinence) prior to study entry through
Day +100 visit. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she must inform her treating physician immediately.

- Able to understand and willing to sign an Institutional Review Board (IRB) approved
written informed consent document.

Exclusion Criteria:

- Prior exposure to elotuzumab or pomalidomide.

- Received systemic multiple myeloma therapy post-relapse/progression. Patients that
received 1-2 cycles of salvage therapy, local radiation, and/or corticosteroids
post-relapse/progression are eligible if there was no further disease progression
following administration.

- More than one prior transplant prior to study entry with the exception of tandem
transplantation. Tandem transplantation is defined as two autologous stem cell
transplants that occur within 9 months of one another, and the patient did not have
disease progression in the period between the two transplants.

- Presence of peripheral neuropathy ≥ grade 3 based on National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events (CTCAE) v 4.0

- History of plasma cell leukemia or MM central nervous system (CNS) involvement.

- Receiving renal replacement therapy, hemodialysis, or peritoneal dialysis.

- Diagnosed with another concurrent malignancy requiring treatment.

- Known HIV or active hepatitis A, B, or C. Antidoby testing not required for screening

- Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in
elotuzumab, formulation, or recombinant protein

- Receiving any other investigational agents within 14 days prior to enrollment.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
arrhythmia.

- Pregnant and/or breastfeeding. Females of childbearing potential must have two
negative pregnancy tests. The first test should be performed within 10-14 days of
study entry, and the second test within 24 hours prior to prescribing pomalidomide.